公开(公告)号：US20220380420A1

公开(公告)日：2022-12-01

申请号：US17817084

申请日：2022-08-03

Applicant: StemRIM Inc. ,  OSAKA UNIVERSITY

Inventor： Katsuto TAMAI ,  Takashi SHIMBO ,  Takehiko YAMAZAKI

IPC: C07K14/47 ,  A61P17/06

Abstract: The present inventors discovered that an HMGB1 fragment peptide having a specific amino acid sequence exhibits an effect of suppressing erythema, scaling (desquamation), and thickening (infiltration) of the skin in an animal model of psoriasis. Based on these findings, pharmaceutical compositions for the prevention and/or treatment of psoriasis, which comprise the HMGB1 fragment peptide having the specific amino acid sequence are provided.

公开(公告)号：US20220265787A1

公开(公告)日：2022-08-25

申请号：US17631072

申请日：2020-07-30

Applicant: STEMRIM INC. ,  OSAKA UNIVERSITY

Inventor： Katsuto TAMAI ,  Takashi SHIMBO ,  Takehiko YAMAZAKI

IPC: A61K38/57 ,  A61K9/00 ,  A61P1/04 ,  A61P43/00 ,  C12N5/0775

Abstract: The present disclosure includes a composition for promoting growth or suppressing decrease of mesenchymal stem cells comprising serpin A3.

公开(公告)号：US20210024594A1

公开(公告)日：2021-01-28

申请号：US16967919

申请日：2019-02-07

Applicant: StemRIM Inc. ,  OSAKA UNIVERSITY

Inventor： Katsuto TAMAI ,  Takashi SHIMBO ,  Takehiko YAMAZAKI

IPC: C07K14/47 ,  A61P17/06

Abstract: The present inventors discovered that an HMGB1 fragment peptide having a specific amino acid sequence exhibits an effect of suppressing erythema, scaling (desquamation), and thickening (infiltration) of the skin in an animal model of psoriasis. Based on these findings, pharmaceutical compositions for the prevention and/or treatment of psoriasis, which comprise the HMGB1 fragment peptide having the specific amino acid sequence are provided.

公开(公告)号：US20180055886A1

公开(公告)日：2018-03-01

申请号：US15674835

申请日：2017-08-11

Applicant: GENOMIX CO., LTD. ,  OSAKA UNIVERSITY

Inventor： Katsuto TAMAI ,  Takehiko YAMAZAKI ,  Takenao CHINO ,  Yasufumi KANEDA

IPC: A61K35/28 ,  C12N5/0775

CPC classification number: A61K35/28 ,  A61K2035/124 ,  C12N5/0663

Abstract: Biologically low invasive vessels are filled with biological factors that have the activity of mobilizing specific functional cells in the body. The vessels are indwelled in the body. After specific functional cells are mobilized into the vessels, the vessels are removed from the body to collect functional cell populations mobilized to the vessels. Alternatively, the cells are directly collected from the vessels indwelled in the body.

公开(公告)号：US20220088083A1

公开(公告)日：2022-03-24

申请号：US17423285

申请日：2020-01-17

Applicant: OSAKA UNIVERSITY

Inventor： Katsuto TAMAI ,  Yasushi KIKUCHI ,  Tomoki TAMAKOSHI

IPC: A61K35/28 ,  A61K38/39 ,  A61K9/00 ,  C07H21/02 ,  A61P17/00 ,  C12N15/90

Abstract: The present disclosure relates to a composition for use in the treatment of dystrophic epidermolysis bullosa, comprising a cell obtained from a patient with dystrophic epidermolysis bullosa, wherein the cell is a mesenchymal stem cell and genetically modified to produce type VII collagen. The present disclosure also relates to a composition for use in the treatment of dystrophic epidermolysis bullosa, comprising a cell that produces type VII collagen, wherein the composition is to be administered into a blister.